Cellectis S.A.
CLLS
Rank in Stocks
#20397
Cellectis S.A., a clinical-stage biotechnology company founded in 1999 and... Cellectis S.A., a clinical-stage biotechnology company founded in 1999 and headquartered in Paris, France, concentrates on immuno-oncology. The firm engineers therapeutic solutions utilizing gene-edited T-cells, which are modified to display chimeric antigen receptors (CARs) for the specific identification and destruction of cancer cells. Its operations are divided into two principal segments: Therapeutics and Plants. The company's pipeline features several allogeneic CAR T-cell product candidates. These include UCART19, aimed at CD19-expressing hematologic malignancies such as acute lymphoblastic leukemia; ALLO-501 and ALLO-501A, developed to treat relapsed or refractory diffuse large B-cell lymphoma and follicular lymphoma; ALLO-316, targeting renal cell carcinoma; UCART123, for acute myeloid leukemia; and UCART22, addressing B-cell acute lymphoblastic leukemia. Additionally, Cellectis is advancing UCARTCS1 and ALLO-715 for the treatment of multiple myeloma. Cellectis has forged significant strategic partnerships and alliances with companies including Allogene Therapeutics, Inc., Les Laboratoires Servier, The University of Texas M.D. Anderson Cancer Center, and Iovance Biotherapeutics. It also maintains a strategic research and development collaboration with Cytovia Therapeutics, Inc.
Share Price
$1.12
Last synced: 2026-11-09
Market Cap
$85.31M
Change (1 day)
4.67%
Change (1 year)
-69.89%
Country
Stock data: Financial Modeling PrepΒ·Updated Β·Not investment adviceΒ·How we calculate this
Trade Cellectis S.A. (CLLS)
Category
Healthcare
EPS for Cellectis S.A. (CLLS)
EPS as of June 2026 TTM: $-0.66
According to Cellectis S.A.'s latest financial reports, its current EPS (TTM) is $-0.66. At the end of 2025 the company had an EPS of $-0.68, a decrease compared to its 2024 EPS of $-0.41.
EPS history for Cellectis S.A. from 2007 to 2026
EPS at the end of each year
| Year | EPS | Change |
|---|---|---|
| 2026 (TTM) | $-0.66 | -2.94% |
| 2025 | $-0.68 | 65.85% |
| 2024 | $-0.41 | -76.84% |
| 2023 | $-1.77 | -24.03% |
| 2022 | $-2.33 | -13.38% |
| 2021 | $-2.69 | 57.31% |
| 2020 | $-1.71 | -20.09% |
| 2019 | $-2.14 | 10.88% |
| 2018 | $-1.93 | -30.58% |
| 2017 | $-2.78 | 53.59% |
| 2016 | $-1.81 | 174.24% |
| 2015 | $-0.66 | -73,433.33% |
| 2014 | 0.00 | -100.02% |
| 2013 | $-4.08 | 175.68% |
| 2012 | $-1.48 | -32.42% |
| 2011 | $-2.19 | 188.16% |
| 2010 | $-0.76 | 94.87% |
| 2009 | $-0.39 | -3,077.10% |
| 2008 | $0.01 | -104.23% |
| 2007 | $-0.31 | 0.00% |
EPS for similar companies or competitors
| Company | EPS | EPS Difference | Country |
|---|---|---|---|
| $15.66 | -2,472.73% |
US
|
|
| $-7.07 | 971.21% |
US
|
|
| $-5.29 | 701.52% |
AU
|
|
| $12.88 | -2,051.53% |
BE
|
|
| $21.56 | -3,366.67% |
NL
|
Questions about Cellectis S.A.'s earnings per share (EPS)
What is Cellectis S.A.'s earnings per share (EPS)?
Cellectis S.A.'s earnings per share (EPS) over the last twelve months is $-0.66, as of Jun 2026.
What was Cellectis S.A.'s earnings per share (EPS) in 2025?
In 2025, Cellectis S.A.'s earnings per share (EPS) was $-0.68, compared with $-0.41 in 2024.
How has Cellectis S.A.'s earnings per share (EPS) changed since 2020?
From 2020 to 2025, Cellectis S.A.'s earnings per share (EPS) was highest in 2024 ($-0.41) and lowest in 2021 ($-2.69).
How does Cellectis S.A.'s earnings per share (EPS) compare with similar companies?
Cellectis S.A.'s earnings per share (EPS) ($-0.66) is higher than that of 2 of the 5 similar companies listed above. The highest among them is Argenx SE, with $21.56.